Joyce O'Shaughnessy

Joyce O'Shaughnessy is a prolific breast cancer clinical trialist with one of the largest breast cancer clinical trial portfolios in North America. She has contributed to development of PARP inhibitors in BRCA-mutated TNBC and was involved in trials establishing multiple standard-of-care regimens in triple-negative breast cancer. She is highly sought as a speaker and educator in breast oncology and has been involved in first-in-human studies of many agents that subsequently received FDA approval. Her community oncology practice model has made her a bridge between academic and community settings.